RE:So, about those 4 drugs CXR bought last quarter...2 were pipeline drugs. It didn't close until June 1st. 2016. Rev should be 3.5M in Q3. So say 2M EBITDA in Q3.
select1011 wrote: ....when at least one good analyst asks for details about this acquisition tomo, what the drugs are, and what the contribution to Q2 revs are of these drugs. are all the longs on this board ok to accept an answer that might be something like, 'cant tell you because of competitive reasons'? That would be a classic WTF moment.